| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 05/22/2001 | US6235285 An isolated polypeptide comprising a heterologous amino acid sequence fused to specific polynucleotide sequence |
| 05/22/2001 | US6235284 Synthetic polypeptides belonging to the hepatitis C virus (HCV) and which can be used especially for detecting the latter |
| 05/22/2001 | US6235283 An isolated polypeptide encoded by a polynucleotide sequence that hybridizes to the complementary strand of an isolated polynucleotide sequence encoding specific amino acid sequence; produces immune response against tick infestationinfestation |
| 05/22/2001 | US6235282 Vaccinal fluid water-in-oil emulsions containing a metabolizable oil |
| 05/22/2001 | US6235281 Use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6 |
| 05/22/2001 | CA1341235C Modular assembly of antibody genes, antibodies prepared thereby and use |
| 05/17/2001 | WO2001035102A2 Diagnosis and treatment of malignant neoplasms |
| 05/17/2001 | WO2001034809A2 Staphylococcus epidermidis nucleic acids and proteins |
| 05/17/2001 | WO2001034805A2 Human vanilloid receptor gene |
| 05/17/2001 | WO2001034802A2 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 05/17/2001 | WO2001034801A2 Recombinant gelatin in vaccines |
| 05/17/2001 | WO2001034800A1 19 human secreted proteins |
| 05/17/2001 | WO2001034799A1 6 human secreted proteins |
| 05/17/2001 | WO2001034795A2 Casb7435 polypeptide, nucleic acid encoding it, and their uses in treatment and diagnosis |
| 05/17/2001 | WO2001034794A1 Casb7434, an antigen over-expressed in colon cancer |
| 05/17/2001 | WO2001034768A2 15 human secreted proteins |
| 05/17/2001 | WO2001034653A2 Protein present at the surface of hematopoietic stem cells of the lymphoid line and of nk cells, and uses thereof |
| 05/17/2001 | WO2001034651A1 Antibodies binding a non naturally occurring enantiomer (l-biotin) and their use as targeting agents |
| 05/17/2001 | WO2001034646A2 Recombinant gelatins |
| 05/17/2001 | WO2001034640A2 Peptide (virip) which inhibits a circulating virus in humans and the use thereof |
| 05/17/2001 | WO2001034638A1 PROCESS FOR CORRECTION OF A DISULFIDE MISFOLD IN Fc MOLECULES |
| 05/17/2001 | WO2001034636A1 Gridlock nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 05/17/2001 | WO2001034621A1 Kringle domain-containing polynucleotides, polypeptides, and antibodies |
| 05/17/2001 | WO2001034617A2 Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| 05/17/2001 | WO2001034574A1 Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
| 05/17/2001 | WO2001034205A2 Use of lytic toxins and toxin conjugates |
| 05/17/2001 | WO2001034195A1 Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5 |
| 05/17/2001 | WO2001034194A1 Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy |
| 05/17/2001 | WO2001034193A1 Plant lectins as mucosal adjuvants |
| 05/17/2001 | WO2001034192A2 Improved method of immunization |
| 05/17/2001 | WO2001034191A1 Cross-protective salmonella vaccines containing an avirulent salmonella choleraesuis strain |
| 05/17/2001 | WO2001034190A2 Live bacterial vaccines against escherichia coli o157:h7 |
| 05/17/2001 | WO2001034189A2 Vaccines for mycoplasma bovis and methods of use |
| 05/17/2001 | WO2001034188A1 Malaria vaccine |
| 05/17/2001 | WO2001034187A2 Preparation and method for prevention of coccidiosis |
| 05/17/2001 | WO2001034186A1 Compositions and methods for modifying an immune response against tropomyosin |
| 05/17/2001 | WO2001034185A2 Induction of mucosal immunity by vaccination via the skin route |
| 05/17/2001 | WO2001034184A2 Methods and compositions for protection against bovine herpesvirus 1 |
| 05/17/2001 | WO2001026646A8 NUTRACEUTICAL PRODUCTS CONTAINING SAMe AND DIETARY SUPPLEMENTS AND METHOD OF MANUFACTURING AND USE THEREOF |
| 05/17/2001 | WO2001023417A3 Human tumor-associated lak-4p related polynucleotides and polypeptides and their uses |
| 05/17/2001 | WO2001022992A3 Influenza vaccine |
| 05/17/2001 | WO2001019861A3 Apo-2 receptor antibodies |
| 05/17/2001 | WO2001012598A9 METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |
| 05/17/2001 | WO2001009339A3 Moraxella catarrhalis antigen basb117 |
| 05/17/2001 | WO2001009309A3 RESCUE OF MUMPS VIRUS FROM cDNA |
| 05/17/2001 | WO2001005427B1 Psca: prostate stem cell antigen and uses thereof |
| 05/17/2001 | WO2001005425A3 Combined preparations comprising daunorubicin derivatives and her2 antibodies |
| 05/17/2001 | WO2001004157A3 NOVEL METHOD AND COMPOSITION FOR INHIBITION OF ANGIOGENESIS USING ANTAGONISTS BASED ON MMP-9 AND β1 INTEGRINS |
| 05/17/2001 | WO2000049038A9 Synthetic peptide of regulatory virus protein r (vpr) of human immunodeficiency virus type 1 (hiv-1) and the utilization thereof |
| 05/17/2001 | WO1999058562A3 Novel compounds |
| 05/17/2001 | WO1999044620A9 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 05/17/2001 | US20010001310 Bispecific antibodies for retargeting anticancer cytotoxic lymphocytes |
| 05/17/2001 | US20010001290 Methods for enhancing the production of viral vaccines in cell culture |
| 05/17/2001 | DE19954514A1 Manipulating activity of cells ex vivo, useful e.g. in immunotherapy of cancer or viral infection, by treating the cells with antigens, adjuvants and stimulants |
| 05/17/2001 | DE10044129A1 New autogenous vaccine useful in the treatment of autoimmune and allergic diseases |
| 05/17/2001 | CA2428827A1 Human vanilloid receptor gene |
| 05/17/2001 | CA2391421A1 Compositions and methods for modifying an immune response against tropomyosin |
| 05/17/2001 | CA2391369A1 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 05/17/2001 | CA2391299A1 Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| 05/17/2001 | CA2391203A1 Cross-protective salmonella vaccines containing an avirulent salmonella choleraesuis strain |
| 05/17/2001 | CA2390999A1 Induction of mucosal immunity by vaccination via the skin route |
| 05/17/2001 | CA2390995A1 Recombinant gelatin in vaccines |
| 05/17/2001 | CA2390613A1 Vaccines for mycoplasma bovis and methods of use |
| 05/17/2001 | CA2390438A1 19 human secreted proteins |
| 05/17/2001 | CA2390412A1 Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy |
| 05/17/2001 | CA2390374A1 Diagnosis and treatment of malignant neoplasms |
| 05/17/2001 | CA2390304A1 Live bacterial vaccines against escherichia coli o157:h7 |
| 05/17/2001 | CA2389722A1 15 human secreted proteins |
| 05/17/2001 | CA2389550A1 Gridlock nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 05/17/2001 | CA2389386A1 Antibodies binding a non naturally occurring enantiomer (l-biotin) and their use as targeting agents |
| 05/17/2001 | CA2389330A1 Kringle domain-containing polynucleotides, polypeptides, and antibodies |
| 05/17/2001 | CA2389204A1 Protein present at the surface of hematopoietic stem cells of the lymphoid line and of nk cells, and uses thereof |
| 05/17/2001 | CA2388912A1 6 human secreted proteins |
| 05/17/2001 | CA2388643A1 Use of lytic toxins and toxin conjugates |
| 05/17/2001 | CA2388477A1 Recombinant gelatins with uniform molecular weight |
| 05/17/2001 | CA2359955A1 Human vanilloid receptor gene |
| 05/17/2001 | CA2325226A1 Use of polypeptides or nucleic acids encoding these for the diagnosis or treatment of skin disorders, and their use for the identification of pharmacologically active substances |
| 05/16/2001 | EP1099759A2 Vibrio cholerae vaccine candidates and methods of their constructing |
| 05/16/2001 | EP1098981A1 A mutant human hepatitis b viral strain and uses thereof |
| 05/16/2001 | EP1098980A2 $i(STREPTOCOCCUS SUIS) VACCINES AND DIAGNOSTIC TESTS |
| 05/16/2001 | EP1098979A2 Fap alpha-specific antibody with improved producibility |
| 05/16/2001 | EP1098975A1 Orphan cytokine receptor |
| 05/16/2001 | EP1098970A1 Human sbpsapl gene with homology to the prosaposin family of neurotrophic factors |
| 05/16/2001 | EP1098961A1 Interferon inducing genetically engineered attenuated viruses |
| 05/16/2001 | EP1098960A2 Agents for the immunotherapy of tumoral diseases |
| 05/16/2001 | EP1098910A1 Antigenic complex comprising immunostimulatory peptide, cd4, and chemokine receptor domain for hiv treatment and immune disorders |
| 05/16/2001 | EP1098909A1 Hybrid human/rodent igg antibody to cd3, and methods of its construction |
| 05/16/2001 | EP1098908A2 Anti-ccr2 antibodies and methods of use therefor |
| 05/16/2001 | EP1098902A1 Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides |
| 05/16/2001 | EP1098665A1 Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
| 05/16/2001 | EP1098664A2 Conjugates for treating inflammatory disorders and associated tissue damage |
| 05/16/2001 | EP1098661A2 Gnrh vaccines for suppressing reproductive behavior in animals |
| 05/16/2001 | EP1084709A9 Oral recombinant lactobacilli vaccines |
| 05/16/2001 | EP0994948B1 Tgf beta rii receptor nucleic sequence, coded peptide, and uses |
| 05/16/2001 | EP0810870B1 Isolated tumor rejection antigen precursor mage-2 derived peptides, and uses thereof |
| 05/16/2001 | EP0753009B1 Malaria peptides |
| 05/16/2001 | CN1295623A Self-replicating vector for DNA immunication against HIV |
| 05/16/2001 | CN1295620A Protein expression in baculovirus vector expression system |
| 05/16/2001 | CN1295618A Porcing reproductive and respiratory syndrome oral vaccine production in plants |
| 05/16/2001 | CN1295616A Tumor-associated antigen derivatives from MAGE family, and nucleic acid sequence encoding them |